MGTX MeiraGTx
Price Chart
Executive Summary
MeiraGTx reported financial results for 2025, highlighted by a significant decline in service revenue and a net loss reduction to $114.2M, alongside transformative strategic collaborations with Lilly and Hologen that brought in $75M and $200M, respectively. The company received FDA Breakthrough Therapy Designation for AAV2-hAQP1 in xerostomia and RMAT for AAV-GAD in Parkinson’s, marking key clinical advancements. Despite declining core revenues, non-dilutive funding and expanded pipelines bolster near-term runway into 2027.
Key Financial Metrics
Actionable Insight
While fundamental service revenue is declining, the influx of non-dilutive capital and regulatory milestones suggest de-risking of key programs. Traders should monitor the April 16, 2026 program update for AAV2-hAQP1 commercial data and watch for initiation of the AAV-GAD Phase 3 trial as near-term catalysts. The stock may react positively to clinical progress despite weak core revenue trends.
Key Facts
- FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia
- Strategic collaboration with Hologen yielded $200M upfront and up to $230M in committed funding for AAV-GAD development
- Lilly collaboration brought $75M upfront and potential for over $400M in milestones for AAV-AIPL1 and ocular assets
- Service revenue dropped 80.7% YoY to $6.4M due to completion of PPQ services under J&J agreement
- License revenue surged to $75.0M from $0 in 2024 due to Lilly upfront payment
- Net loss narrowed to $114.2M in 2025 from $147.8M in 2024
- Cash and equivalents declined to $65.9M as of Dec 31, 2025, from $105.7M in 2024
- Company expects sufficient capital into second half of 2027, including $95M remaining from Hologen deal
- Phase 3 study of AAV-GAD in Parkinson’s expected to initiate in coming months with Hologen AI support
- Ribo-leptin IND planned for 2026; riboswitch platform advancing in metabolic and neuropathic pain
Financial Impact
Revenue mix shifted dramatically: $75M in non-recurring license revenue offsetting $26.9M drop in service revenue. Strategic deals added $275M in non-dilutive capital. R&D increased $10.1M to $129.6M as clinical programs advanced.
Risk Factors
- Heavy reliance on milestone-dependent partnerships (Lilly, J&J) for future funding
- Service revenue collapse indicates shrinking core operations as J&J manufacturing work ends
- No near-term product revenue; all value hinges on clinical and regulatory success
- High cash burn: $65.9M cash with $75M debt due by mid-2027 creates future financing risk
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262943 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
21d ago
|
144
| $9.58 $10.00 | ▲ +4.38% | ▲ +2.58% | $9.21 (−3.86%) |
|
May 14, 2026
26d ago
|
8-K
| $9.95 $9.49 | ▼ −4.62% | ▼ −3.91% | $9.21 (−7.44%) |
|
May 14, 2026
26d ago
|
Press Release
| $9.95 $9.49 | ▼ −4.62% | ▼ −3.91% | $9.21 (−7.44%) |
|
Apr 24, 2026
6w ago
|
8-K
| $9.23 $9.22 | ▼ −0.11% | ▼ −1.02% | $9.21 (−0.22%) |
|
Apr 16, 2026
7w ago
|
8-K / 424B5
| $10.12 $9.23 | ▼ −8.79% | ▼ −9.35% | $9.21 (−8.99%) |
|
Apr 16, 2026
7w ago
|
8-K
| $9.48 $9.32 | ▼ −1.69% | ▼ −2.67% | $9.21 (−2.85%) |
|
Apr 16, 2026
7w ago
|
Press Release
| $9.48 $9.32 | ▼ −1.69% | ▼ −2.67% | $9.21 (−2.85%) |
|
Apr 16, 2026
7w ago
|
8-K
| $9.48 $9.32 | ▼ −1.69% | ▼ −2.67% | $9.21 (−2.85%) |
|
Apr 16, 2026
7w ago
|
Press Release
| $9.48 $9.32 | ▼ −1.69% | ▼ −2.67% | $9.21 (−2.85%) |
|
Mar 26, 2026
10w ago
|
Press Release
| $7.53 $9.18 | ▲ +21.91% | ▲ +20.28% | $9.21 (+22.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access